6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
7m ago	Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
7m ago	Surface Transforms plc – in Administration, Sale of Business and Assets
8m ago	Guerbet: Changes to the Composition of Guerbet’s Board of Directors.
8m ago	RENAULT S.A. : disclosure of trading in own shares from May 15 to May 20, 2026
8m ago	Assystem: Combined General Meeting of 22 May 2026 - Voting Results and dividend for financial year 2025

About

13.32AUD-0.82 -5.80%

Closed • Updated at 16:42 GMT+00:00

Market Cap$3.43B

Volume4.88M

Beta0.75

RSI36.96

Gross Margin53.15%

Health TechnologyBiotechnology

Telix Pharmaceuticals Limited — investor relations, events, news, and company updates on 6ix.

Latest News

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

TLX101-Px (Pixlumi®) MAA Accepted in Europe

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

Community Chat

Ask AI